Clinicians should consider dupilumab as a therapeutic option for bullous pemphigoid due to its ability to clear blistering and pruritus safely, according to a study.Bullous pemphigoid (BP) is a ...

Patients with bullous pemphigoid experienced symptom improvement with dupilumab treatment, according to a study.“Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases ...

Treatment with dupilumab led to significant improvements in disease remission in patients with bullous pemphigoid, an autoimmune blistering skin disease. The phase 2/3 LIBERTY-BP ADEPT trial ...

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD Provided by GlobeNewswire Mar 8, 2025, 10:00:00 AM ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron ...

“People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options ...

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial ...

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com November 10, 2023 09:08 AM Eastern Standard Time ...

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly ...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Published Jun 20, 2025 1:00am EDT ...

This approval in the U.S. is important for the thousands of patients living with bullous pemphigoid, and we look forward to working with regulators around the world to bring this innovative ...

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP) Provided by GlobeNewswire Jun 19, 2025, 10:00:53 PM ...